Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma

Abstract

Two Chimeric Antigen Receptor (CAR) T-cell therapies are now approved for the treatment of relapsed and refractory large cell lymphomas, with many others under development. The dawn of CAR T-cell therapy in non-Hodgkin Lymphoma (NHL) has been characterized by rapid progress and high response rates, with a subset of patients experiencing durable benefit. In this review, we describe commercially available and investigational CAR T-cell therapies, including product characteristics and clinical outcomes. We review patient selection, with an emphasis on sequencing cell therapies including autologous and allogeneic stem cell transplantation. Finally, we discuss durability of response, highlighting mechanisms of escape and investigational approaches to prevent and treat relapse after CAR T cell therapy. K E Y W O R D Schimeric antigen receptor T Cell, Gene therapy, Lymphoma